Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IBEX Technologies Inc V.IBT

Healthcare Biotechnology
IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a... see more

Bullboard (TSXV:IBT)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by nozzpackon Dec 21, 2021 6:16pm

RE:IBT Principal Shareholder owns 16.47%

That's correct 6.5 million shares held by insiders . Not much selling which is an affirmative flag..
46
Discussion
Post by guarantor1on Dec 21, 2021 12:45pm

Absolutely Remarkable IBT Trading

Hits an 18 yr High, on a 75% gain in 2 days, with less than 600k share traded, which = only 2.5% of the Float And then an absolutely minimal rush to exit the stock -  light volume with ...more  
99
Post by guarantor1on Dec 21, 2021 9:44am

IBT Principal Shareholder owns 16.47%

Neil Subin controls the LLoyd Miller Family Estate IBT Estate And Paul Baehr is next in line with approx 9.9% PRINCIPAL SHAREHOLDER As at November 28, 2019, to the best knowledge of the ...more  
94
Discussion
Comment by nozzpackon Dec 21, 2021 9:12am

RE:RE:Could Afford a dividend

Thank you. I prefer to use cash for growth but realize that a dividend would do wonders for the share price. However, if this niche is constrained in terms of acquisition opps, and we have ...more  
43
Discussion
Comment by guarantor1on Dec 21, 2021 5:41am

RE:Could Afford a dividend

Paul Baehr has been asked about a dividend, in the past...and he was not a big fan of the concept. Quarterly financials can be very erratic, and he wants a cushion. And I suspect initial DAO ...more  
57
Discussion
Post by nozzpackon Dec 20, 2021 1:16pm

Could Afford a dividend

1 cent semiannually would costs just $500,000 per year. They have the cash and cash flow, with the caveat that such a dividend would be reviewed annually..
87
Discussion
Comment by nozzpackon Dec 19, 2021 6:00pm

RE:Potential Market for IBEX's vegetal Diamine Oxidase

Thank you  for that informative post. It's very difficult to find good proxies in this niche for Ibex. The major shareholder has held here for quite a while. At some point in a robust market ...more  
51
Discussion
Post by guarantor1on Dec 19, 2021 3:18pm

Potential Market for IBEX's vegetal Diamine Oxidase

From this Feb's Paul Baehr interview -  https://www.youtube.com/watch?v=CnEck4TM_Ec&t=1454s at 22:30;  discussing Diamine Oxidase a synopsis : he estimates the US and European ...more  
162
Discussion
Post by nozzpackon Dec 19, 2021 8:02am

Strong Growth Forecast for Nutraceuticals

Trying to scope potential revenues for their new vegetal DAO. Will they also target the domestic pet and livestock market ? https://www.yahoo.com/now/global-nutraceuticals-market-reach-441 ...more  
173
Comment by nozzpackon Dec 18, 2021 4:48pm

RE:RE:RE:Listed Competitors of IBT

Look, we are on the Ibex BB. Pump your own investments on their own BBS..
58
Discussion
Comment by nozzpackon Dec 18, 2021 1:39pm

RE:Listed Competitors of IBT

Ceapro talk the talk but very slow to walk the walk. Been there already,  just like Jemtec which has no growth profile and limited market. IBT shines by example..
47
Discussion
Post by nozzpackon Dec 18, 2021 1:30pm

EV to Ebitda Fair Value

The EV to Ebitda multiple for this niche is 14.32.......see link below Annualizing Q1 Ebitda of $763,000 , we have $3 million in Ebitda per year. So, we have EV = $3 million times 14.32 = $43 ...more  
109
Post by nozzpackon Dec 18, 2021 10:19am

Listed Competitors of IBT

Brutally undervalued with a market cap of $11 m.. IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting ...more  
134
Discussion
Comment by guarantor1on Dec 17, 2021 1:44pm

RE:New Bioenzyme Product DAO

And keep in mind that Ibex DAO is vegetal based.... "Excess of histamine in gut lumen generates a pronounced gastrointestinal discomfort, which may include diarrhea and peristalsis dysfunctions ...more  
70
Discussion
Post by nozzpackon Dec 17, 2021 10:21am

New Bioenzyme Product DAO

Seems like a significant market for this nutraceutical being developed for marketing in 2022 https://dr-healthcare.com/en/category/news/publications-in-the-media/
110
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities